Penlan Pharmaceuticals logo
Request a formulary pack or sales call

Product Information

Mechanism of Action (7)

Potassium citrate inhibits the formation of kidney stones through the following mechanism:

Diagram explaining the effects of potassium citrate: it increases alkali load and raises urinary pH, reduces tubular citrate reabsorption leading to increased urinary citrate, increases uric acid solubility, reduces calcium oxalate saturation, and inhibits crystallisation of calcium salts.

Indicated for:

  • The treatment of patients with kidney stones and hypocitraturia, or chronic calcium oxalate stones.
  • The treatment and prevention of recurrent uric acid lithiasis with or without calcium lithiasis and cystine lithiasis.
  • The treatment of renal tubular acidosis with calcium nephrolithiasis.

Take three times daily with meals.

White plastic bottle of Renodyra modified-release potassium citrate tablets (1080mg) standing behind a pile of off-white tablets on a white background.

Improved patient adherence via a palatable, convenient tablet formulation

Summary of Product Characteristics